When was HDAX founded?

HDAX was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is HDAX located?

HDAX is headquartered in Mississauga, Canada.

Who is the current CEO of HDAX?

Nabanita Nawar of HDAX. They have also founded 1 company.

How many employees does HDAX have?

As of Dec 31, 2024, the latest employee count at HDAX is 3.

Is HDAX a funded company?

HDAX is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Sep 05, 2024.

When was the latest funding round of HDAX?

HDAX's latest funding was a $***** Seed round on Sep 05, 2024, with participation from 5 investors. Its primary sector is Neurology. In Canada, the Neurology sector has seen $175M in funding in 2026 to date.

Where does HDAX rank among its competitors?

HDAX ranks 22nd amongst 39 active competitors, of which 13 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was SciNeuro, which secured $53M in Dec, 2025.

Who are the top competitors of HDAX?

HDAX's top competitors include Cingulate, SciNeuro and STALICLA. Among them, SciNeuro secured the most recent funding round in December, 2025.

HDAX - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule drugs to treat cancer and CNS disorders. The company is developing epigenetic medicines targeting HDAC proteins. The company's product includes HDAC6 inhibitors that help in the selective inhibition of disease-relevant HDAC isoforms.

Website: hdaxtx.com
Social
Email ID: *****@hdaxtx.com

Key Metrics

Founded Year

2021

Location

Mississauga, Canada

Stage

Seed

Total Funding

$3.2M in 1 round

Latest Funding Round

Seed, Sep 05, 2024, $*****

Investors

FACIT & 6 more

Ranked

22^nd among 39 active competitors

Employee Count

3 as on Dec 31, 2024

Similar Companies

Cingulate & 41 more

View HDAX's full profile

HDAX has raised a total funding of $3.2M over 1 round. Its latest funding round was a Seed round on Sep 05, 2024 for $*****. 5 investors participated in its latest round. HDAX has 7 institutional investors.

Here is the list of recent funding rounds of HDAX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2024	1133013	Seed	7012427	9258253	2349270	3834389

Access funding benchmarks and valuations. Sign up today!

View details of HDAX's funding rounds and investors

The founders of HDAX are Nabanita Nawar and Pimyupa Manaswiyoungkul. Nabanita Nawar is the CEO of HDAX.

Here are the details of HDAX's key team members:

Nabanita Nawar: Co-Founder & CEO of HDAX.
Contact Info: 1 email address
Pimyupa Manaswiyoungkul: Co-Founder & COO of HDAX.

View details of HDAX's Founder profiles and Board Members

HDAX's employee count trend

HDAX has 3 employees as of Dec 24. Here is HDAX's employee count trend over the years:

Uncover HDAX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HDAX include Cingulate, SciNeuro and STALICLA. Here is the list of Top 10 competitors of HDAX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	The Werth Family Foundation, Lincoln Park Capital ... & 2 others	58/100
2nd	SciNeuro 2020, Shanghai (China), Series A	Developer of therapeutic solutions for the treatment of CNS disorders	$153M	Arch Venture Partners, LAV & 6 others	57/100
3rd	STALICLA 2017, Geneva (Switzerland), Series B	Manufacturer of precision medicinea for neurodevelopmental disorders	$24.1M	Addex Therapeutics, SPRIM Global Investments ... & 7 others	56/100
4th	NEOS Therapeutics 2008, Grand Prairie (United States), Public	Speciality Company developing extended release drugs for CNS disorders using proprietary technology platform	$94.6M	Essex Capital, Presidio Partners & 7 others	50/100
5th	Metispharma 2020, Hangzhou (China), Series D	Developer of AI-driven nanomedicine platforms for targeted drug delivery systems	$55.5M	Daxing Industrial Investment Fund, Beijing Medical and Health Industry Investment Fund ... Read more	49/100
6th	Curemark 2004, New York City (United States), Series B	Developer of therapeutics for the treatment of Autism and other neurological diseases	$96M	Springboard Enterprises, Grimley Capital & 1 others	49/100
7th	Scienture 2019, Hauppauge (United States), Public	Developer of therapeutics for CNS, oncology, and cardiovascular disease	-	-	48/100
8th	Connecta Therapeutics 2018, Barcelona (Spain), Seed	Developer of drugs for treating neurological disorders	$4.89M	Inveready, DST & 4 others	47/100
9th	Nura Bio 2018, San Francisco (United States), Series A	Provider of solution for diagnosis of a neurological disorder and neuroprotective medicines	$141M	The Column Group, Sanofi Ventures & 2 others	47/100
10th	Markit 2003, London (United Kingdom), Public	Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders	-	-	47/100
22nd	HDAX 2021, Mississauga (Canada), Seed	Developer of small molecule drugs to treat cancer and CNS disorders	$3.2M	Ontario Centre of Innovation, FACIT & 5 others	33/100